

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated August 24, 2023 (the “**Prospectus**”) issued by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (i) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (ii) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People’s Republic of China with limited liability)*

**(Stock Code: 1541)**

## **PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

### **PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Overall Coordinators (for themselves and on behalf of the International Underwriters) on Thursday, September 28, 2023 in respect of an aggregate of 917,800 H Shares, representing approximately 5.35% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering, at HK\$18.60 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%).

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, September 28, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by Morgan Stanley Asia Limited, the Stabilizing Manager, or its affiliates or any person acting for it, during the stabilization period are set out in this announcement.

## **PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Overall Coordinators (for themselves and on behalf of the International Underwriters) on Thursday, September 28, 2023 in respect of an aggregate of 917,800 H Shares, representing approximately 5.35% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering.

The over-allotment Shares will be issued and allotted by the Company pursuant to the exercise of the Over-allotment Option at HK\$18.60 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%), being the Offer Price per H Share under the Global Offering.

## **APPROVAL OF LISTING**

Approval for the listing of and permission to deal in the over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on Wednesday, October 4, 2023.

## SHARE CAPITAL UPON COMPLETION OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-allotment Option is as follows:

Description of Shares	Immediately before the completion of the partial exercise of the Over-allotment Option		Immediately after the completion of the partial exercise of the Over-allotment Option	
	Number of Shares	Approximate percentage to the total share capital of the Company (%)	Number of Shares	Approximate percentage to the total share capital of the Company (%)
Unlisted Shares in issue <sup>(1)</sup>	145,607,656	39.01	145,607,656	38.92
H Shares converted from Unlisted Shares <sup>(2)</sup>	210,485,039	56.39	210,485,039	56.26
H Shares issued under the Global Offering	17,147,200	4.59	18,065,000	4.83
<b>Total</b>	<b>373,239,895</b>	<b>100.00</b>	<b>374,157,695</b>	<b>100.00</b>

Notes:

- (1) The Unlisted Shares in issue refer to 36,780,390 Unlisted Shares held by ZJ Leading Initiating VC, 35,091,495 Unlisted Shares held by Dr. Tian, 19,263,240 Unlisted Shares held by Lapam Capital, 10,862,055 Unlisted Shares held by Zhangjiang Sci & Tech, 7,758,630 Unlisted Shares held by Jiaxing Changxian, 7,419,847 Unlisted Shares held by Jiaxing Changyu, 7,214,085 Unlisted Shares held by Suzhou Likang Equity Investment Centre (Limited Partnership) (蘇州禮康股權投資中心(有限合夥)), 3,463,673 Unlisted Shares held by Gongqing City Ruiji Fund III Investment Partnership (共青城瑞吉三期投資合夥企業(有限合夥)), 3,350,655 Unlisted Shares held by Sunshine Life Insurance Corporation Limited (陽光人壽保險股份有限公司), 2,633,332 Unlisted Shares held by Shengzhou Minglang Industry Development Equity Investment Fund Partnership (Limited Partnership) (嵊州市銘朗產業發展股權投資基金合夥企業(有限合夥)), 2,347,150 Unlisted Shares held by Shihezi Yaluo Equity Investment Partnership (Limited Partnership) (石河子市雅羅股權投資有限合夥企業), 2,271,083 Unlisted Shares held by Granite Peak Limited, 1,731,836 Unlisted Shares held by Borah Peak Limited, 1,697,445 Unlisted Shares held by Nanjing Xingjian Ruiying Equity Investment Partnership (Limited Partnership) (南京星健睿贏股權投資合夥企業(有限合夥)), 1,227,717 Unlisted Shares held by Gongqing City Chuangdongfang Huaying Equity Investment Partnership (Limited Partnership) (共青城創東方華盈股權投資合夥企業(有限合夥)), 1,066,815 Unlisted Shares held by Shanghai Sci-Tech Innovation Center Capital Fund I (Limited Partnership) (上海科創中心壹號股權投資基金合夥企業(有限合夥)), 753,840 Unlisted Shares held by Suzhou Lirun Equity Investment Centre (Limited Partnership) (蘇州禮潤股權投資中心(有限合夥)) and 674,370 Unlisted Shares held by Wuhu Bloomage Langya Healthcare Industry Investment Partnership (Limited Partnership) (蕪湖華熙朗亞健康產業投資合夥企業(有限合夥)).

- (2) Following the completion of the Global Offering and according to the approval issued by the CSRC on January 31, 2023, 210,485,039 Unlisted Shares was converted into H Shares on a one-for-one basis and listed on the Stock Exchange for trading.

## **USE OF PROCEEDS**

The Company will receive additional net proceeds of approximately HK\$16.83 million (after deducting the underwriting commissions and other estimated expenses payable by the Company in connection with the partial exercise of the Over-allotment Option) for the 917,800 H Shares to be issued and allotted pursuant to the partial exercise of the Over-allotment Option. The Company intends to utilize the additional net proceeds, on a pro rata basis, for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, September 28, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Morgan Stanley Asia Limited, the Stabilizing Manager, or its affiliates or any person acting for it, during the stabilization period are set out below:

- (i) over-allocation of an aggregate of 917,800 H Shares under the International Offering, representing approximately 5.35% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (ii) successive purchases of an aggregate of 200 H Shares at the price of HK\$18.60 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) on the market during the stabilization period, representing approximately 0.001% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). The last purchase made by the Stabilizing Manager or its affiliates or any person acting for it, on the market during the course of the stabilization period was on September 6, 2023 at the price of HK\$18.60 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%), being the Offer Price per H Share under the Global Offering;

- (iii) the sale of an aggregate of 200 H Shares at the price of HK\$27.05 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) on the market during the stabilizing period, representing approximately 0.001% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option; and
- (iv) the partial exercise of the Over-allotment Option by the Overall Coordinators (for themselves and on behalf of the International Underwriters) on Thursday, September 28, 2023 in respect of an aggregate of 917,800 H Shares, representing approximately 5.35% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at HK\$18.60 per H Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%), being the Offer Price per H Share under the Global Offering, to cover over-allocations under the International Offering.

The portion of the Over-allotment Option which has not been exercised by the Overall Coordinators (for themselves and on behalf of the International Underwriters) lapsed on Thursday, September 28, 2023.

## **PUBLIC FLOAT**

Immediately after the end of the stabilization period and the partial exercise of the Over-allotment Option, (i) the number of H Shares in public hands will be 154,725,761 H Shares, representing approximately 41.35% of the total issued share capital of the Company which satisfies Rule 8.08(1) of the Listing Rules, and (ii) the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Hong Kong, September 28, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Tian Wenzhi, Mr. Li Song and Ms. Song Ziyi as executive Directors, Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors and Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*